Cancer is on course to be the leading cause of death in the EU by 2035. Europe's population is ageing rapidly, and obesity ...

MedImmune will explore the target, linker, warhead selection: Do's and Don’ts; five rights of creation of the best optimized fit-for-purpose ADCs; internalisation of ADCs – how to improve ...

Start ups and entrepreneurs in the UK who have developed, or are looking to create, a digital healthcare solution are being invited to submit entries to a new prize fund organised by MedImmune.

This article highlights several inspiring men and women working across academia and industry who are breaking barriers and ...

Maryland is a big player in the biotech and pharmaceutical industries, and one company that stands out is MedImmune. Founded in 1988 and located in Gaithersburg, MedImmune works hard to create new ...

Maryland’s biotech industry plays a pivotal role in advancing global health initiatives. This vibrant sector is characterized ...

MedImmune and Astellas Pharma. ImmunoGen is working with Genentech, Sanofi–Aventis, Amgen, Biogen Idec, Biotest and Bayer Schering Pharma. With so many companies seeking access to ADC technology ...

Objective Microscopic colitis (MC) is a common cause of chronic diarrhoea, often with additional symptoms. No validated instruments exist to assess disease activity in MC, making it difficult to ...

2 Division of Preventive and Behavioral Medicine, University of Massachusetts School of Medicine, Worcester, Massachusetts, USA 3 Division of Clinical Immunology and Rheumatology, University of ...

The FimH vaccine is not new. It was originally licensed by MedImmune (a wholly-owned subsidiary of AstraZeneca) in the late 1990s and entered phase 1 and phase 2 clinical trials before being dropped ...

Competition page helps you compare MedImmune Inc. with its sector peers on key parameters.